1,376 results on '"Valk, Peter"'
Search Results
2. A Possible Artefact in Gel Chromatography of 99mTc Compounds
3. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
4. Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials
5. Prognostic impact of CEBPA mutational subgroups in adult AML
6. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia
7. STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia
8. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
9. PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy
10. Figure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
11. Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
12. Supplementary Tables S1-S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
13. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
14. A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction
15. EXABS-100-AML Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
16. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
17. Future Developments: Measurable Residual Disease
18. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
19. Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.
20. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
21. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
22. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia
23. PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse
24. Disruption of CSF-1R signaling inhibits growth of AML with inv(16)
25. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
26. Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes
27. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
28. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
29. The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia
30. Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
31. Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.
32. Future Developments: Measurable Residual Disease
33. Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia
34. Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice
35. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia
36. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
37. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
38. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
39. AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities
40. AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia
41. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
42. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
43. High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
44. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
45. P318: LOSS OF SCARNA12 RESULTS IN ABERRANT SPLICING OF TARGET GENES AND DOWNREGULATION OF P53 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)
46. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
47. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
48. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
49. Table S1 from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
50. Table S3 (part 3) from Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.